Guillain-Barre Syndrome

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy that presents with rapidly progressive bilateral limb weakness, areflexia, and a monophasic disease course reaching nadir within 4 weeks in 80% of patients ^[9]D5[11]C4.

Also Called / Synonyms

• Acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating subtype
• Landry-Guillain-Barré-Strohl syndrome (historical)
• Acute flaccid paralysis syndrome
• Miller Fisher syndrome (MFS), a clinical variant
• Bifacial weakness with paresthesias (BFP), a variant linked to anti-gelsolin-3 IgG ^[14]B3b

Key Terms

• Albuminocytologic dissociation (ACD): elevated CSF protein (>0.45 g/L) with normal white cell count (<50 cells/μL), present in 70% of patients but highly dependent on timing of lumbar puncture ^[5]B2b.
• Brighton criteria: diagnostic certainty levels 1-4 based on clinical features, CSF, and electrophysiology ^[11]C4.
• Modified Erasmus GBS Outcome Score (mEGOS): predicts inability to walk unaided at 4 and 26 weeks using age, preceding diarrhea, and limb weakness severity ^[6]B2b.
• Rasch-built Overall Disability Scale (R-ODS): linearly weighted 24-item scale capturing activity and participation limitations ^[4]C4.
• Treatment-related fluctuation (TRF): clinical deterioration within 8 weeks of onset after initial improvement or stabilization, occurring in 10% of patients ^[11]C4.
• Acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP): a mimic that presents acutely but has a relapsing or progressive course beyond 8 weeks or three or more TRFs ^[13]B3b.

Classification of Variants

GBS is classified into electrophysiological and clinical subtypes. The table below summarizes the major variants.

Clinical Significance

GBS is the most common cause of acute flaccid paralysis worldwide, with an incidence of 1-2 per 100,000 person-years; up to 22% require mechanical ventilation and mortality ranges from 2% to 17% depending on region ^{[1]B2b[9]D5[10]B2b}.

The following section details the pathophysiology and neuroanatomic localization that underlies these diverse clinical presentations.

Pearl: The Brighton criteria require bilateral limb weakness, areflexia, monophasic course, and CSF albuminocytologic dissociation; however, normal CSF protein does not exclude GBS, especially within the first 4 days of symptom onset ^[5]B2b[11]C4.

The classification of Guillain-Barré syndrome (GBS) into acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) reflects distinct but overlapping pathophysiological mechanisms that converge on a final common pathway of complement-mediated nodal injury ^{[14]B3b[27]D5}.

Molecular mimicry and the antigenic trigger

Infection is the initiating event in 60-70% of cases. Campylobacter jejuni is the most thoroughly characterized trigger: its lipo-oligosaccharides mimic human gangliosides, particularly GM1, GD1a, GD1b, and GT1a ^[25]D5[27]D5. The resultant cross-reactive IgG autoantibodies are the primary pathogenic effectors. Mycoplasma pneumoniae elicits anti-galactocerebroside (GalC) antibodies, especially IgG subclass, which are associated with cranial nerve involvement and a better outcome ^[22]B3b. Other triggers, norovirus, dengue virus, Zika virus, and SARS-CoV-2, operate through similar or alternative mechanisms; in COVID-19 -associated GBS, enhanced IgG reactivity to adenoviral proteins (rather than SARS-CoV-2 spike protein) has been reported, suggesting prior adenoviral sensitization as a cofactor ^{[35]B3b[43]C4}.

Autoantibody targets and neuroanatomic localization

Anti-ganglioside antibodies bind to the nodes of Ranvier, where gangliosides are densely expressed ^[27]D5[36]D5. In AMAN, anti-GM1 and anti-GD1a IgG predominantly target the motor axolemma at distal nodes, a preference dictated by the fine specificity of the antibody rather than by ganglioside quantity ^[38]D5. This distal-dominant gradient explains the early loss of deep tendon reflexes and the rapid, often reversible, conduction block observed in AMAN ^[37]C4. In AIDP, a newly identified autoantibody, anti-gelsolin-3 IgG1, binds to periaxonal myelin at the paranodal axon-myelin interface, targeting the non-compact myelin that anchors the terminal loops ^[14]B3b. This finding reclassifies AIDP as a nodo-paranodopathy, unifying the pathophysiology across subtypes ^[14]B3b.

Complement-mediated nodal injury and conduction failure

Antibody binding activates the classical complement cascade at the node. Deposition of C3d and C5b-9 (membrane attack complex) disrupts voltage-gated sodium channel clusters and ankyrin G, the molecular scaffold maintaining nodal architecture ^{[14]B3b[36]D5}. In AMAN, this complement-dependent injury proceeds through calpain activation, leading to collapse of the nodal gap and loss of axonal excitability ^[36]D5. Conduction block can be reversible (rapid recovery within 3 weeks) or progress to axonal degeneration, a continuum that explains the spectrum from mild weakness to flaccid paralysis ^[37]C4. In AIDP, complement attack on the periaxonal myelin triggers vesicular demyelination, which precedes macrophage infiltration ^[14]B3b.

T-cell involvement and cytokine amplification

T lymphocytes contribute through the inducible costimulator (ICOS) pathway: ICOS-expressing T cells interact with ICOS ligand (ICOS-L) on macrophages within the nerve, perpetuating inflammation ^[29]C4. Cytokine profiling reveals that myeloid-derived IL-8 is a central mediator, and LIF (leukemia inhibitory factor) and CD8A are novel biomarkers, with LIF receptors expressed on endothelial and stromal cells ^[45]B3b. CAR T-cell therapy -associated GBS may represent a distinct, cytokine-driven mechanism without classical antibody involvement, as 60% of cases show facial nerve involvement and limited response to IVIG ^[39]C4.

Susceptibility factors

Host factors determine subtype and severity. Preceding infection type dictates the ganglioside target: C. jejuni strains with GM1-like epitopes favor AMAN, whereas M. pneumoniae favors GalC-associated AIDP ^{[22]B3b[27]D5}. Age >60 years, rapid progression, and prolonged mechanical ventilation are red flags for anti-pan-neurofascin nodo-paranodopathy, a mimic requiring rituximab ^[23]C4. Stroke-induced immunodepression may unmask GBS after cerebral infarction, broadening the etiological spectrum ^[44]C4.

Pearl: The distal nodes of Ranvier are the primary battlefield in both AMAN and AIDP, complement-mediated injury at this site explains the rapid onset of conduction block, the potential for early recovery (if nodal architecture is preserved), and the rationale for complement-directed therapies such as eculizumab ^{[21]A1b[36]D5}.

The immune-mediated attack on peripheral nerves is most often triggered by an antecedent infection, and the epidemiology reflects this infectious link. Guillain-Barré syndrome (GBS) has an annual incidence of 1.5-1.9 per 100,000 population, based on UK and Japanese nationwide data ^{[51]B2c[64]B2c}. It affects all ages, but incidence rises with age; the median age at onset is 57 years, and there is a slight male predominance (60%) ^{[52]B2b[62]C4}. GBS is the most common cause of acute flaccid paralysis worldwide ^[31]D5.

Temporal and Seasonal Trends

GBS incidence shows significant seasonal variation, with peaks in winter and early spring, consistent with the seasonality of respiratory and gastrointestinal infections ^[66]B2c. During the COVID-19 pandemic, non-pharmaceutical interventions reduced exposure to common infectious triggers, leading to a 9% decline in GBS incidence (relative risk 0.91, 95% CI 0.83-0.99) in Japan ^[64]B2c. Similar reductions were observed in the UK ^[51]B2c and in a natural-experiment study from Japan that confirmed a statistically significant level reduction in GBS incidence after April 2020 ^[33]B2c.

Risk Factors

Approximately 75% of GBS cases are preceded by an infectious illness within the prior 6 weeks ^[64]B2c. The strongest evidence links GBS to Campylobacter jejuni enteritis, cytomegalovirus, Epstein-Barr virus, hepatitis E virus, Zika virus, and SARS-CoV-2 ^{[50]B2b[60]B2b[68]B2b[72]C4[76]B2a}. The table below summarizes key risk factors with their effect sizes.

Vaccine-Associated Risk in Context

The risk of GBS after vaccination is very small. For seasonal influenza vaccine, no significant association was found in a large French study (IRR 1.02) ^[53]B2b. For COVID-19 vaccines, adenovirus-vector platforms (ChAdOx1-S, Ad26.COV2.S) carry a small excess risk of about 5-7 cases per million doses, while mRNA vaccines show no consistent signal ^[52]B2b. Crucially, the risk of GBS following SARS-CoV-2 infection itself is up to 617-fold higher than after COVID-19 vaccination ^[69]C4. The benefits of vaccination far outweigh this rare adverse event ^{[48]B2a[52]B2b}.

Pearl: When evaluating a patient with acute flaccid paralysis, always ask about recent infection (especially diarrheal or respiratory illness) within the prior 6 weeks; the absence of an antecedent infection should prompt consideration of alternative diagnoses such as nutritional neuropathy or paraneoplastic syndromes ^{[77]C4[49]B3b}.

The clinical syndrome emerges 1-4 weeks after an antecedent infection, with symptoms progressing over days to weeks. The hallmarks are symmetrical, ascending flaccid weakness and areflexia, but the spectrum of presentation is broad, and recognition of atypical variants is critical for timely diagnosis.

Presenting Symptoms

Weakness typically begins in the lower extremities and ascends to the arms, trunk, and cranial nerves over hours to days. Disease nadir occurs within 2 weeks in 80 % of patients and within 4 weeks in 97 % ^[11]C4. Paresthesias (numbness, tingling) in the feet and hands are common early symptoms, often preceding weakness. Low back pain is frequent. In preschool children, the most common presentations are refusal to walk and leg pain (65 %), leading to initial misdiagnosis in 68 % of cases - often mistaken for myopathy, tonsillitis, meningitis, or hip disorders ^[81]B2b. An antecedent gastrointestinal or respiratory infection is reported in about 72 % of patients ^[86]B2b; the most common serologically confirmed trigger is Campylobacter jejuni (30 %), followed by Mycoplasma pneumoniae (10 %), cytomegalovirus (4 %), and hepatitis E virus (3 %) ^[86]B2b. Zika virus infection has a median incubation of 7 days before GBS onset ^[83]C4.

Neurological Examination Findings

Motor: Symmetrical weakness, predominantly affecting proximal and distal muscles of the lower limbs, then upper limbs. The Medical Research Council (MRC) sum score quantifies severity. In severe cases, quadriplegia develops. Reflexes: Deep tendon reflexes are absent or markedly reduced in paretic limbs in 91 % of patients at presentation and in all patients during follow-up ^[11]C4. An exception is the acute motor axonal neuropathy (AMAN) variant, where reflexes may be preserved or even brisk ^[27]D5. Sensory: Mild to moderate loss of vibration and proprioception in a distal distribution is typical; sensory loss may be absent in pure motor variants. Cranial nerves: Bilateral facial weakness is the most common cranial nerve deficit, occurring in 50 % of Zika-associated GBS ^[83]C4 and in 62 % of patients with Zika virus infection ^[88]B2b. Bulbar weakness (dysphagia, dysarthria, stridor) signals risk of aspiration and respiratory failure. Respiratory: Diaphragmatic and intercostal weakness leads to ventilatory failure. A critical threshold for intubation is forced vital capacity (FVC) < 15 mL/kg or a rapid decline in serial measurements; inability to count in one breath or paradoxical abdominal breathing are bedside clues. Autonomic: Labile blood pressure, cardiac arrhythmias, ileus, and urinary retention occur in up to 30 % of patients, more often in the demyelinating subtype ^[27]D5.

Phenotypic Variants

GBS encompasses several distinct clinical variants, each with characteristic features and antibody associations (Table 1).

Treatment-related fluctuations (TRF) occur in about 10 % of patients, always within 8 weeks of onset; more than 2 fluctuations or deterioration after 8 weeks should prompt consideration of acute-onset chronic inflammatory demyelinating polyneuropathy (CIDP) ^[79]B2b.

Red Flags

• Rapid progression (nadir < 1 week) predicts severe disease and axonal subtype ^[27]D5.
• Bulbar weakness (dysphagia, stridor) signals impending respiratory failure.
• Autonomic instability (wide blood pressure swings, bradycardia, tachycardia) requires ICU monitoring.
• Inability to walk unaided at presentation is a poor prognostic sign ^[25]D5.
• Children are frequently misdiagnosed; a high index of suspicion is needed when a toddler refuses to walk after an infection ^[81]B2b.

Atypical Presentations

GBS can mimic other disorders. Uncommon presentations include:

• Acute abdominal pain as the first symptom, delaying diagnosis ^[94]C4.
• Asymmetric weakness - consider vasculitic neuropathy (e.g., eosinophilic granulomatosis with polyangiitis) ^[19]C4.
• Poor response to IVIG with postural tremor and proteinuria - test for anti-CNTN1 antibodies (autoimmune nodopathy) ^[95]C4.
• Recurrent acute axonal neuropathy in children - suspect biallelic RCC1 variants ^[80]C4.
• COVID-19 -associated GBS - no distinct clinical phenotype, but higher intubation rates due to pulmonary involvement ^[51]B2c.
• Parvovirus B19 - diagnosed by CSF targeted next-generation sequencing ^[96]C4.

Pearl: The key to early diagnosis is recognizing that areflexia and progressive symmetrical weakness over days are the diagnostic sine qua non; any deviation - such as asymmetry, preserved reflexes in paretic limbs, or deterioration beyond 8 weeks - should prompt a search for mimics, including vasculitis, acute-onset CIDP, or genetic neuropathies.

The diagnosis of Guillain-Barré syndrome is primarily clinical, resting on the progressive nature of symmetric weakness, areflexia, and a monophasic course. Supportive investigations, CSF analysis, nerve conduction studies (NCS), and, in selected cases, antibody serology, strengthen diagnostic certainty and help exclude mimics. The Brighton Collaboration criteria provide a standardized framework for diagnostic certainty, ranging from Level 1 (highest) to Level 4 (lowest) ^[11]C4.

Diagnostic Criteria (Brighton and NINDS)

The Brighton criteria require bilateral limb weakness, decreased or absent deep tendon reflexes in affected limbs, a monophasic illness course, and time from onset to nadir between 12 hours and 28 days, followed by a plateau phase ^[11]C4. Ancillary features include CSF albuminocytologic dissociation and electrophysiologic findings consistent with a neuropathy. In a validation study of 494 patients, 61% met Brighton Level 1 (all features present), 33% Level 2, and 6% Level 4; patients with variant presentations (e.g., paraparetic GBS) or early CSF/lumbar puncture may fall into lower levels ^[11]C4. The National Institute of Neurological Disorders and Stroke (NINDS) criteria similarly emphasize progressive weakness, areflexia, and supportive laboratory/electrophysiologic data. Brighton Level 1 requires all four core features, plus CSF protein elevation and NCS abnormalities ^[11]C4.

CSF Analysis

Albuminocytologic dissociation, elevated protein with a normal white cell count (<50 cells/μL), is the hallmark, but its sensitivity depends on timing. Among 1,231 patients in the International GBS Outcome Study, 70% had albuminocytologic dissociation overall, increasing from 57% when CSF was sampled within 4 days of weakness onset to 84% when sampled after 4 days ^[5]B2b. A normal CSF protein, especially early, does not exclude GBS ^[5]B2b. An elevated CSF protein is associated with a demyelinating subtype, proximal or global weakness, and a lower likelihood of independent walking at week 2 and week 4 (OR 0.42 and 0.44, respectively) ^[5]B2b. CSF cell count is <5 cells/μL in 83% of patients; 16% have 5-49 cells/μL, and only 1% have ≥50 cells/μL ^[5]B2b. A pleocytosis >50 cells/μL should prompt a search for alternative diagnoses such as infectious myelitis or HIV-associated polyradiculoneuropathy. In the Brighton criteria, a CSF cell count <50 cells/μL is required for Level 1 diagnostic certainty ^[11]C4.

Neurophysiology (NCS/EMG)

Nerve conduction studies are essential for confirming peripheral nerve involvement, identifying the electrophysiologic subtype, and assessing prognosis. In the classic demyelinating form (acute inflammatory demyelinating polyneuropathy, AIDP), findings include prolonged distal motor latencies, slowed conduction velocities, conduction block, and temporal dispersion. Axonal subtypes (acute motor axonal neuropathy, AMAN; acute motor-sensory axonal neuropathy, AMSAN) show reduced compound muscle action potential (CMAP) amplitudes with relatively preserved conduction velocities. In a prospective study of 154 patients, demyelinating features were more common in those who required mechanical ventilation (85% vs 51%, p=0.0003) ^[1]B2b. The proximal/distal CMAP ratio of the peroneal nerve <55.6% predicted respiratory failure with a probability of needing ventilation <2.5% when the ratio was >55.6% and vital capacity >81% of predicted ^[1]B2b. NCS also help distinguish GBS from chronic inflammatory demyelinating polyneuropathy (CIDP): in CIDP, conduction abnormalities persist for >8 weeks, whereas in GBS, they evolve acutely. At least one NCS should be performed within the first week to document the subtype; however, 41% of patients may not fulfill strict electrodiagnostic criteria for a distinct subtype early in the course ^[11]C4.

Antibody Testing

Routine testing for anti-ganglioside antibodies is not required for diagnosis ^[3]D5. However, antibody testing can support the diagnosis in uncertain cases or identify specific variants. Anti-GM1 IgG is associated with AMAN, preceding Campylobacter jejuni infection, and a more severe axonal course ^[3]D5. Anti-GQ1b IgG is highly specific for Miller Fisher syndrome (MFS) and its overlap with Bickerstaff brainstem encephalitis ^[87]D5. In MFS, anti-GQ1b is present in >90% of patients ^[87]D5. Anti-GD1b IgG is linked to acute sensory ataxic neuropathy ^[3]D5. Antibodies against nodal/paranodal proteins (neurofascin-155, contactin-1, Caspr1) define autoimmune nodopathy, which may present with a GBS-like acute/subacute onset but typically shows poor response to IVIg and excellent response to rituximab ^[23]C4[12]C4. Testing for anti-pan-neurofascin antibodies should be considered in patients >60 years, with severe/progressive GBS, prolonged mechanical ventilation, or relapse after initial improvement ^[23]C4.

Differential Diagnosis

The differential includes conditions that cause acute or subacute flaccid paralysis. A focused diagnostic workup, including MRI of the spine (to exclude compressive myelopathy), NCS, and CSF analysis, is essential.

Diagnostic Algorithm

1. Clinical suspicion - Progressive symmetric weakness, areflexia, with or without sensory symptoms, evolving over days to 4 weeks. Exclude motor neuron disease, myopathy, and neuromuscular junction disorders. 2. CSF analysis - Lumbar puncture (if no contraindication) to document albuminocytologic dissociation. Perform early (within 4 days) but recognize that sensitivity is low; repeat if needed. 3. NCS/EMG - Confirm peripheral nerve involvement and classify subtype. 4. Antibody testing - Reserve for atypical presentations (MFS, acute-onset CIDP, autoimmune nodopathy) or when clinical features suggest a specific variant. 5. Consider alternative diagnoses - Spinal MRI, serology for HIV, Lyme, CMV, EBV, and ANCA testing if vasculitis is suspected. 6. Initiate immunotherapy - Do not delay treatment while awaiting test results if the clinical picture is highly suggestive. The Brighton criteria provide a structured approach to diagnostic certainty and are recommended for research and vaccine safety surveillance ^[11]C4.

Pearl: In a patient with rapidly progressive weakness and areflexia, a normal CSF protein within the first 4 days does not rule out GBS; repeat CSF after 4 days or proceed with NCS, do not delay immunotherapy if the clinical picture is typical.

Controversies and Guideline Disagreement

There is no major controversy regarding the diagnostic criteria; however, the role of routine antibody testing remains debated. The American Academy of Neurology and European Federation of Neurological Societies do not recommend routine anti-ganglioside antibody testing, whereas some experts advocate for targeted testing in atypical presentations ^[3]D5. The Brighton criteria are widely used for research but may be less sensitive for variants (e.g., paraparetic GBS, pharyngeal-cervical-brachial variant) ^[85]B2b.

Once the diagnosis is confirmed, the next step is to stratify patients by severity and prognosis using validated scoring systems that directly inform treatment intensity and trial eligibility. These tools convert the clinical presentation into actionable tiers, allowing clinicians to identify patients at highest risk of respiratory failure, poor functional recovery, or death.

GBS Disability Score (Hughes Scale)

The GBS disability score, a 7-point scale (0 = healthy, 1 = minor symptoms but able to run, 2 = able to walk ≥10 m without assistance, 3 = able to walk ≥10 m with assistance, 4 = bedbound or chairbound, 5 = requires mechanical ventilation, 6 = death), is the most widely used outcome measure in clinical trials ^[115]A1a. A score of ≥3 at presentation defines moderate-to-severe disease and is the threshold for initiating immunotherapy. Mild disease (score 2) may not require treatment, though 75% of such patients in the International GBS Outcome Study (IGOS) received IVIg or plasma exchange ^[102]B2b.

Medical Research Council (MRC) Sum Score

The MRC sum score sums the strength of 12 muscles (bilateral shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle dorsiflexion) on a 0-60 scale, with higher scores indicating stronger muscles ^[106]C4. It is a key component of both the mEGOS and EGRIS prognostic models. A score ≤40 at admission is associated with a higher risk of respiratory failure and poor 6-month outcome ^{[47]B2b[67]B2b}.

Rasch-built Overall Disability Scale (R-ODS)

The R-ODS is a 24-item, linearly weighted scale that captures activity and social participation limitations in patients with GBS, chronic inflammatory demyelinating polyradiculoneuropathy, and related disorders ^[4]C4. It provides a wider range of item difficulties than the GBS disability score, better targeting patients at different ability levels, and is increasingly used in research settings.

Prognostic Models: mEGOS and EGRIS

Two validated prognostic models guide clinical decision-making:

mEGOS score ≥6 was used to define poor prognosis in the SID-GBS trial, which found no benefit from a second IVIg course and increased adverse events ^[113]A1b. EGRIS helps decide ICU monitoring: a score of 4-7 indicates a high risk (30-91%) of needing mechanical ventilation within the first week ^[67]B2b. A recalibrated version for Europe/North America more accurately predicts observed risks, which were lower than originally modeled (10% vs 21%) ^[117]B2b.

Biomarkers and Additional Stratifiers

Beyond clinical scores, several biomarkers refine risk stratification:

• CSF protein level: High CSF protein (albuminocytologic dissociation) is associated with a demyelinating subtype, proximal/global weakness, and reduced likelihood of regaining ambulation at 2 and 4 weeks (OR 0.42-0.44) ^[5]B2b. ACD is present in 70% of patients overall, rising to 84% after 4 days from symptom onset.
• Serum albumin: Hypoalbuminemia (<3.5 g/dL) before or after IVIg is associated with respiratory failure, severe muscle weakness, and inability to walk unaided at 6 months ^[116]B2b.
• Galectin-3: Serum galectin-3 levels >6457.5 pg/mL distinguish axonal from demyelinating GBS with AUC 0.84, outperforming neurofilament light chain ^[121]B2b.
• Antibody profiling: Anti-GM1 and anti-GQ1b complex antibodies define motor GBS and Miller Fisher syndrome, respectively, and clusters of antibody reactivity patterns correlate with regional variation, electrophysiologic subtype, and time to regaining ambulation ^[62]C4.
• Antecedent infection: C. jejuni seropositivity is associated with lower MRC sum score at nadir and longer time to walk independently ^[86]B2b.
• Demographic factors: Age >50 years, bulbar weakness, and need for mechanical ventilation are independent risk factors for death ^[57]B2b. In pregnancy, bulbar weakness (OR 5.29) and autonomic dysfunction (OR 7.17) predict ICU admission ^[119]C4.

These stratification tools, clinical scores, CSF findings, serum biomarkers, and antibody profiles, transform the heterogeneous GBS phenotype into a quantifiable risk spectrum, enabling personalized treatment decisions and appropriate resource allocation.

Pearl: Use the mEGOS at day 7 (not at admission) for the best prediction of 6-month outcome (AUC 0.87), and the EGRIS to decide ICU transfer: a score of 4 or more gives a ≥30% risk of mechanical ventilation within the first week ^{[47]B2b[67]B2b}.

Once severity is stratified (see Section 6) and the diagnosis of GBS is confirmed, acute management follows two parallel tracks: emergency stabilization of the neurologic crisis and immediate attack-abortion with immunotherapy. The first priority is airway protection and hemodynamic monitoring , because respiratory failure occurs in 20-30% of patients and autonomic dysfunction can precipitate lethal arrhythmias ^[125]D5 (5).

Step 1: Emergency Stabilization

Admit all patients with rapid progression, bulbar weakness, or autonomic signs to an intensive care unit (ICU) or step-down unit with continuous cardiorespiratory monitoring. Bulbar weakness (OR 5.29, P=0.001) and autonomic dysfunction (OR 7.17, P<0.001) are strongly predictive of ICU requirement ^[119]C4 (4). In the general GBS population, 64% of pregnant patients require ICU admission and 45% require mechanical ventilation ^[119]C4 (4). Measure forced vital capacity (FVC) every 4-6 hours; elective intubation is indicated when FVC falls below 20 mL/kg, or when bulbar weakness impairs secretion clearance. Address autonomic lability ( hypertension , hypotension, bradycardia, tachycardia) with short-acting agents and avoid vagal stimulation during suctioning .

Step 2: First-Line Immunotherapy, Attack Abortion

Initiate disease-modifying therapy as soon as the diagnosis is established, ideally within the first week of symptom onset. Two treatments are of equivalent efficacy:

Intravenous immunoglobulin (IVIG): 0.4 g/kg/day infused over 5 consecutive days (total dose 2 g/kg) ^[44]C4 (4). The Lancet review confirms this regimen as optimal alongside plasma exchange ^[125]D5 (5). AAN guidelines classify IVIG as established for severe GBS (Level A) ^[8]A1c (1c). Start within 48 hours of admission if possible.

Plasma exchange (PE): 5 sessions of 1-1.5 plasma volumes over 1-2 weeks, exchanging with 5% albumin. The AAN guidelines state that PE is established as effective and should be offered in severe AIDP/GBS (Class I studies, Level A) ^[8]A1c (1c). PE is also probably effective for mild GBS (Level B) ^[8]A1c (1c).

Choice between IVIG and PE: Both are equally effective; the decision depends on availability, contraindications, and patient characteristics. IVIG is preferred in patients with hemodynamic instability, difficult venous access, or coagulopathy. PE is preferred in patients with hyperviscosity or IgA deficiency. Combine the two sequentially only in refractory cases, there is no evidence that routine combination improves outcomes ^[125]D5 (5).

Step 3: Monitoring and Escalation

Assess neurologic status daily using the Medical Research Council (MRC) sum score (range 0-60) and the Hughes Functional Grade. If no improvement is seen by day 7-10 after starting first-line therapy, consider a second course of IVIG or a switch to PE. Limited evidence supports a repeat IVIG dose (0.4 g/kg/day × 3-5 days) in non-responders, but controlled trials are lacking. In rare relapsing GBS (e.g., associated with Graves’ disease or neoplasm), FcRn inhibition with efgartigimod has been reported ^[132]C4 (4), though this is not standard first-line therapy and should be reserved for atypical refractory cases.

Biomarker guidance: Serum neurofilament light chain (NfL) levels correlate with disease severity at admission (r=0.38, P<0.001) and predict poor long-term outcomes (OR 3.74) ^[128]A1a (1a). Although not routinely used for acute decision-making, rising NfL may identify patients who require more aggressive therapy. Peripherin (a PNS-specific axonal biomarker) and periaxin (a Schwann-cell biomarker) are being investigated but are not yet in clinical use ^{[126]B3b[127]B3b} (3b).

Step 4: Supportive Care During Acute Phase

• Ventilatory support: Noninvasive ventilation is not recommended; early intubation is safer when bulbar weakness or declining FVC is present.
• Pain management: Neuropathic pain (present in up to 50%) may be treated with gabapentinoids or tricyclic antidepressants; avoid opioids if possible.
• Thromboembolism prophylaxis: Low-molecular-weight heparin and compression stockings until the patient is ambulatory.
• Gastrointestinal and bladder care: Nasogastric tube if swallowing is unsafe; intermittent catheterization for urinary retention.

Step 5: Transition to Long-Term Management

Once the patient has plateaued neurologically (no further decline for 24-48 hours), transfer to a neurologic ward or rehabilitation unit. The acute immunotherapy phase is complete; the subsequent phase focuses on neurorehabilitation and long-term disease-modifying therapy only if a chronic inflammatory demyelinating polyneuropathy (CIDP) evolves (see Section 10).

Table 1: Comparison of First-Line Immunotherapies for GBS

What NOT to Do

• Do NOT use corticosteroids as monotherapy, they are ineffective in GBS and may worsen outcomes ^[125]D5 (5).
• Do NOT delay immunotherapy awaiting confirmatory electrophysiology; treat empirically if clinical suspicion is high and CSF shows albuminocytologic dissociation ^[129]B2b (2b).
• Do NOT combine IVIG and PE routinely, sequential therapy does not improve outcomes and increases cost ^[125]D5 (5).

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence.

Pearl: Initiate IVIG 0.4 g/kg/day for 5 days or plasma exchange 5 sessions immediately upon diagnosis of GBS; do not await further deterioration, and avoid corticosteroids as monotherapy since they are ineffective ^{[8]A1c[125]D5}.

After the initial course of intravenous immunoglobulin (IVIg) or plasma exchange , the definitive management of Guillain-Barré syndrome shifts to meticulous supportive care and rehabilitation, as no long-term disease-modifying therapy has been proven to alter the trajectory of recovery beyond the acute phase. The evidence ladder for additional interventions is steep: the highest-level trials have failed to demonstrate benefit, and promising phase 1 data await confirmation.

Step 1: Rehabilitation, the backbone of long-term care

A systematic review of three randomized controlled trials found that various rehabilitation interventions (including physical therapy, occupational therapy, and neuromuscular electrical stimulation) correlate with improved patient well-being, but the low quality and small sample sizes preclude definitive conclusions ^[135]A1a (1a). One pilot RCT showed that adding yogic relaxation, pranayama (breathing exercises), and guided meditation to conventional rehabilitation significantly improved sleep quality (Pittsburgh Sleep Quality Index, p = 0.04) but not pain, anxiety, depression, or functional status compared with standard care alone ^[142]A1b (1b). Thus, rehabilitation is recommended as standard supportive care, but no specific protocol has been shown to reduce disability more than another.

Step 2: Complement inhibitors, negative trials, no current role

Neither the phase 2 nor the phase 3 trial of eculizumab met its primary endpoint. The phase 2 trial (ICA-GBS) reported a descriptive improvement in GBS disability scores, but the sample was too small (n = 8) for statistical testing ^[140]A1b (1b). The phase 3 trial confirmed no benefit (HR 0.9, 95%; NNT not calculable ^[139]A1b). ANX005 showed acceptable safety and pharmacodynamic evidence of complement blockade, with reductions in neurofilament light chain, but these data are preliminary and not practice-changing ^[137]A1b (1b). Complement inhibition is not recommended for routine use outside of clinical trials.

Step 3: What not to do, no evidence for chronic immunotherapy

Unlike chronic inflammatory demyelinating polyneuropathy (CIDP), GBS is monophasic and does not require maintenance immunosuppression. Repeated courses of IVIg, corticosteroids, or other immunomodulators have not been tested in adequately powered trials and are not supported by the current evidence. The phase 3 eculizumab data ^[139]A1b reinforce that even a potent complement inhibitor, when added to IVIg, does not accelerate recovery. No second-line agent has demonstrated efficacy in patients who do not respond to initial IVIg or plasma exchange.

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence; all major societies recommend IVIg or plasma exchange for acute GBS and do not endorse any long-term immunotherapy. The only controversy is the interpretation of the complement-inhibitor data: the early phase 2 trial ^[21]A1b suggested a possible signal, but the subsequent phase 3 trial ^[139]A1b definitively refuted it. Clinicians should avoid offering eculizumab or other complement inhibitors outside of research protocols.

Pearl: After acute immunotherapy for Guillain-Barré syndrome, no disease-modifying therapy has been shown to improve long-term recovery; rehabilitation remains the cornerstone of definitive management, and complement inhibitors such as eculizumab should not be used.

The evidence ladder described above establishes IVIG and plasma exchange as the cornerstones of acute GBS therapy. This standard was not won quickly; it emerged from a series of landmark trials spanning three decades, while other once-promising approaches were abandoned.

The Pre-Immunotherapy Era

Before the 1980s, GBS was managed with supportive care alone. Mortality rates approached 15% and many survivors were left with permanent disability. The first controlled trial of immunotherapy, a 1978 study of oral prednisolone (60 mg daily tapered over 10 days), found no benefit and a trend toward worse outcomes: control patients improved by 2.5 grades at 3 months vs. 0.9 grades in the steroid group (P < 0.05) ^[151]A1b. This result set the stage for a more rigorous search.

The Plasma Exchange Revolution

The landmark 1985 North American trial randomized 245 patients to plasmapheresis or supportive care. Patients treated with plasma exchange within 7 days of onset had significantly faster improvement at 4 weeks, shorter time to independent walking, and better 6-month outcomes ^[149]A1b. Two subsequent trials confirmed these findings: the French Cooperative Group showed that 4 plasma exchanges reduced the need for mechanical ventilation and accelerated motor recovery, and that albumin was superior to fresh frozen plasma as replacement fluid because of fewer complications ^{[158]A1b[159]A1b}. The French group also established the dose-response relationship: 2 exchanges benefited mild GBS, 4 exchanges benefited moderate GBS, but 6 exchanges offered no advantage over 4 in severe cases [157]. Plasma exchange became the first proven therapy.

IVIG Enters the Arena

In 1992, the Dutch Guillain‑Barré Study Group randomized 150 patients to IVIG 0.4 g/kg/day for 5 days or five plasma exchanges. IVIG was at least as effective: 53% of IVIG patients improved by one grade at 4 weeks vs. 34% with PE (difference 19%, 95% CI 3-34%, P = 0.024), and IVIG had fewer complications and less need for ventilation ^[147]A1b. The 1997 Plasma Exchange/Sandoglobulin Trial of 383 patients confirmed that PE and IVIG had equivalent efficacy and that combining PE followed by IVIG did not confer additional benefit ^[154]A1b. The 2003 AAN practice parameter formally recommended both therapies as first-line options for nonambulant patients, with Level A evidence ^[146]A1c.

The Steroid Trials: A Cautionary Tale

Despite the success of PE and IVIG, steroids continued to be tested. A 1993 double-blind trial of intravenous methylprednisolone 500 mg daily for 5 days in 242 patients found no significant benefit on disability grade at 4 weeks (difference 0.06 grades, 95% CI -0.23 to 0.36) ^[152]A1b. A 2004 trial added methylprednisolone to IVIG in 233 patients; the unadjusted odds ratio for improvement at 4 weeks was 1.68 (95%, P = 0.06), reaching significance only after adjustment for age and baseline disability (OR 1.89) ^[153]A1b. These results were not considered practice-changing, and corticosteroids are now not recommended for GBS (AAN Level A recommendation against use) ^[146]A1c.

Refining the Regimen: Dose, Sequencing, and Rescue

Attempts to improve outcomes by intensifying therapy have largely failed. The SID‑GBS trial (2010-2018) randomized 93 patients with poor prognosis (modified Erasmus GBS Outcome Score ≥ 6) to a second IVIG course 2 g/kg over 5 days or placebo given 7-9 days after the first dose. The adjusted common odds ratio for improvement at 4 weeks was 1.4, and serious adverse events were more frequent in the second-dose group (35% vs. 16%), including thromboembolic events and four deaths ^[113]A1b. A second IVIG course is therefore not recommended. The complement inhibitor eculizumab (900 mg weekly for 4 weeks) was tested in a phase 2 trial of 34 patients with severe GBS; at week 4, 61% of the eculizumab group could walk independently vs. 45% of the placebo group, but the predefined response threshold was not met ^[21]A1b. Larger trials are needed, and eculizumab remains investigational. Immunoadsorption has shown promise in refractory cases but lacks robust comparative data ^[181]C4.

Historical Context: The Vaccine Connection

GBS entered the public consciousness in 1976 when the swine influenza vaccine was associated with an increased risk of the syndrome (approximately 1 excess case per 100,000 vaccinations) ^[172]D5. Subsequent surveillance found that the 2009 H1N1 monovalent inactivated vaccine conferred a modest risk (incidence rate ratio 2.35, 95%), translating to about 1.6 excess cases per million vaccinations ^[48]B2a. This risk consistently outweighed by the benefits of influenza vaccination, and no increased risk of GBS recurrence after SARS‑CoV‑2 vaccination has been observed ^[166]B2b.

Pearl: The history of GBS treatment teaches that only therapies that remove or neutralize circulating pathogenic antibodies (PE and IVIG) have proven benefit; immunomodulation with steroids, despite biological plausibility, is ineffective and may be harmful.

Building on the established efficacy of IVIG and PE, the sequencing, safety monitoring, and de-escalation of immunotherapy in GBS require a structured approach to optimize outcomes and minimize harm. The following protocol integrates evidence from randomized trials and observational data.

Step 1: Initial Immunotherapy Selection

For severely affected patients (unable to walk independently), initiate either IVIG 0.4 g/kg/day × 5 days (total 2 g/kg) or PE 5-7 exchanges over 10-14 days ^[115]A1a (1a). The two modalities are equivalent in efficacy: weighted mean difference on the 7-point disability grade scale at 4 weeks was -0.02 (95% CI -0.25 to 0.20) ^[115]A1a. Choice depends on contraindications (IVIG: IgA deficiency, hyperviscosity; PE: hemodynamic instability, difficult venous access) and availability. In current practice, 97% of severe GBS patients receive one of these therapies ^[102]B2b (2b).

Step 2: Monitoring Response and Escalation

Assess clinical status at 1-2 weeks after treatment initiation using the Hughes Functional Grading Scale. If no improvement or continued deterioration, consider a second immune-modulatory treatment. Among patients who did not improve after initial therapy, 35% received a second treatment in the International GBS Outcome Study ^[102]B2b. Options include:

• Switch to the alternative modality (IVIG → PE or PE → IVIG).
• Immunoadsorption (IA): In a retrospective series of 13 critically ill patients with refractory neuroimmunological disorders (including GBS), intermittent IA improved the modified Rankin Scale (p = 0.02) and reduced serum IgG by a median of 55.6% ^[181]C4 (4). Treatment interruptions occurred in 92% (infection, hypotension) but were manageable.
• Efgartigimod: A case series of 4 acute GBS patients reported favorable outcomes with IV efgartigimod, including 2 who received monotherapy ^[186]C4 (4). Dosing and safety data remain preliminary.

Step 3: Treatment-Related Fluctuations

A treatment-related fluctuation (TRF) occurs in 5% of patients, defined as clinical worsening after initial improvement or stabilization within 8 weeks of treatment ^[102]B2b. Of these, 68% were re-treated with IVIG or PE ^[102]B2b. Re-treatment follows the same dose and schedule as initial therapy. TRFs do not necessarily indicate a chronic course, but distinguishing from acute-onset CIDP is important (see Section 13).

Step 4: De-escalation and Discontinuation

GBS immunotherapy is a single acute course. After completing 5 days of IVIG or 5-7 PE exchanges, no further immunotherapy is indicated unless a TRF or treatment failure occurs. There is no role for maintenance therapy. Corticosteroids are not recommended: oral corticosteroids were associated with significantly less improvement at 4 weeks (WMD -0.82, 95% CI -1.47 to -0.17), and IV methylprednisolone showed no benefit over placebo (WMD -0.17, 95% CI -0.39 to 0.06) ^[115]A1a (1a).

Step 5: Safety Monitoring

Pre-hydrate before IVIG and slow the infusion rate if headache occurs. For PE, maintain calcium supplementation to prevent hypocalcemia from citrate.

What NOT to Do

• Do not use corticosteroids as monotherapy - they are ineffective or harmful ^[115]A1a.
• Do not routinely combine IVIG and PE - one trial (N=148) found no additional benefit from sequential therapy ^[115]A1a.
• Do not continue immunotherapy beyond the initial course unless a clear indication (TRF, failure) arises - prolonged treatment risks adverse effects without evidence of benefit.

Controversies and Guideline Disagreement

No major guideline disagreements were identified in the reviewed evidence. However, practice variability exists: 75% of mild GBS patients (able to walk independently) and 76% of Miller Fisher syndrome patients received immunotherapy despite the absence of trial data supporting efficacy in these subgroups ^[102]B2b (2b). Clinicians should weigh the potential benefit against the lack of evidence when treating mild or variant forms.

Pearl: In GBS, immunotherapy is a single acute course; de-escalation means stopping after 5 days of IVIG or 5-7 exchanges of PE, with re-treatment reserved for treatment-related fluctuations or failure to improve - corticosteroids have no role and may worsen outcomes ^[115]A1a.

Following initiation of immunotherapy, the clinical focus shifts to a structured supportive care and rehabilitation program that directly reduces the 20-30% risk of respiratory failure and the 20% rate of persistent disability despite treatment ^{[125]D5[115]A1a}. This phase addresses autonomic instability, pain, thromboembolic risk, and functional decline through coordinated multidisciplinary interventions.

Respiratory Monitoring

Respiratory failure from diaphragmatic and intercostal weakness is the most life-threatening complication in the acute phase. Forced vital capacity (FVC) should be measured every 4-6 hours in all patients with progressive weakness. The following thresholds guide escalation to intensive care and mechanical ventilation:

Intubation is indicated when FVC falls below 15 mL/kg, MIP is < 20 cm H₂O, or the patient develops hypercapnia, hypoxia, or inability to clear secretions. Elective intubation is safer than emergency intubation in this population.

Autonomic Complications

Autonomic dysfunction occurs in up to 70% of severe GBS cases and manifests as labile hypertension or hypotension, cardiac arrhythmias (sinus tachycardia, bradycardia, atrial fibrillation ), ileus, and urinary retention. Blood pressure fluctuations require careful titration of short-acting agents (e.g., labetalol for hypertension, phenylephrine for hypotension) to avoid overshoot. Continuous telemetry is recommended for patients with bulbar or respiratory involvement. Ileus is managed with nasogastric decompression and prokinetic agents; urinary retention often necessitates intermittent catheterization.

DVT/PE Prophylaxis

Immobility places GBS patients at high risk for venous thromboembolism. Subcutaneous enoxaparin 40 mg once daily (or unfractionated heparin 5000 units three times daily) should be initiated on admission unless contraindicated. Graduated compression stockings and early mobilization further reduce risk.

Pain Management

Pain in GBS is common and has two predominant types: neuropathic pain (burning, tingling, or electric-shock sensations) and nociceptive pain from immobility or nerve root inflammation. Neuropathic pain is reported in 27-31% of patients at 6-12 months after onset ^{[88]B2b[71]A1a}. First-line agents include gabapentin (starting 300 mg three times daily, titrated to 900-3600 mg/day) or pregabalin (75-150 mg twice daily). Amitriptyline (10-50 mg at bedtime) is an alternative, particularly when sleep disturbance is prominent. For acute nociceptive pain, acetaminophen or NSAIDs may be used cautiously, avoiding renal impairment. Opioids are reserved for severe breakthrough pain due to risk of respiratory depression and ileus.

Rehabilitation

Rehabilitation should begin as soon as the patient is medically stable, often while still in the ICU. Early, supervised, individualized exercise programs improve fatigue, functional capacity, and quality of life ^{[188]B2a[131]D5}. Optimal programs include:

• Respiratory muscle training to improve cough and vital capacity.
• Range-of-motion exercises to prevent contractures.
• Strengthening (resistance training) for antigravity muscles.
• Balance and gait training with orthotic support as needed.
• Aerobic conditioning (e.g., stationary cycling) for endurance.

Sessions of 45-60 minutes, 3-4 times per week for at least 12 weeks, are associated with best outcomes ^[188]B2a. The Medical Research Council sum score and Modified Erasmus GBS Outcome Score guide goal setting ^{[131]D5[106]C4}. Occupational therapy addresses fine motor skills and activities of daily living; speech therapy manages dysphagia and communication.

Hospital-Acquired Complications

Prevention of secondary complications is integral to supportive care:

• Ventilator-associated pneumonia : Elevate head of bed to 30-45°, perform oral care with chlorhexidine, and use subglottic secretion drainage if intubated.
• Pressure injuries: Turn every 2 hours, use pressure-relieving mattresses, and inspect skin daily.
• Catheter-associated urinary tract infection: Remove indwelling catheters as soon as possible; use intermittent catheterization if needed.

Complication Overview

Pearl: The single most impactful supportive care intervention in GBS is serial FVC monitoring every 4-6 hours, a decline to < 20 mL/kg or a > 30% drop from baseline should trigger immediate ICU transfer and consideration of elective intubation, which reduces aspiration and hypoxic injury compared with emergency intubation.

Supportive care is the foundation that prevents complications from becoming fatal, but the clinician must anticipate a predictable set of medical threats that arise from the disease itself and from prolonged hospitalization.

Respiratory Monitoring

Respiratory failure is the most immediate threat. Forced vital capacity (FVC) < 20 mL/kg, maximal inspiratory pressure < 30 cm H2O, or a decline of > 30% from baseline are thresholds for considering elective intubation. Intubation is indicated when FVC falls below 15 mL/kg, the patient cannot clear secretions, or signs of respiratory fatigue emerge. Mechanical ventilation is required in 20-30% of patients and is a strong independent risk factor for death ^[57]B2b.

Autonomic Complications

Autonomic dysfunction affects up to 70% of severely affected patients. Manifestations include labile hypertension , hypotension, cardiac arrhythmias, ileus, and urinary retention. Continuous ECG monitoring is recommended for the first week in the ICU. Treat bradyarrhythmias with atropine or temporary pacing; use short-acting antihypertensives (e.g., labetalol) for hypertension, avoiding long-acting agents due to rapid fluctuations.

DVT/PE Prophylaxis

Given universal immobility, all patients should receive low molecular weight heparin (e.g., enoxaparin 40 mg subcutaneously once daily) plus sequential compression devices. No GBS-specific trials exist, but this practice is extrapolated from general ICU thromboprophylaxis guidelines.

Pain Management

Pain is predominantly neuropathic. First-line therapy is gabapentin (starting 300 mg three times daily) or pregabalin (75-150 mg twice daily). For severe pain, cautious opioids may be used, monitoring for respiratory depression. Amitriptyline (10-50 mg at night) is an alternative for burning pain.

Rehabilitation

Begin passive range of motion and early mobilization as soon as medical stability permits. Even after motor recovery, residual symptoms are common: at 6 months, 42.6% report positive sensory symptoms, 30.9% fatigue, and 29.4% subjective limb weakness ^[120]B2b. Occupational and speech therapy are essential for bulbar weakness.

Hospital-Acquired Complications

• Pneumonia: Occurs in ~19% of hospitalized GBS patients; independent risk factors include bulbar palsy, mechanical ventilation, and hyponatremia ^[75]B2b. Prevention: oral care, head -of-bed elevation, early mobilization.
• SIADH: Detected in 48% of patients at some point; associated with bulbar weakness, need for ventilatory support, and longer hospitalization ^[58]B2b. Monitor serum sodium daily; fluid restrict if symptomatic.
• Pressure injuries: Frequent repositioning and specialty mattresses.
• Urinary tract infection: Remove indwelling catheters as soon as possible.

Pearl: The highest risk of death in GBS is not during the progressive phase but during the recovery phase, from respiratory or cardiovascular complications, vigilance must continue until the patient is ambulatory ^[57]B2b.

The preceding complications underscore the importance of early prognostication to guide management and shared decision‑making. Guillain‑Barré syndrome follows a monophasic course: nadir is reached within 2 weeks in 80% of patients and within 4 weeks in 97% ^[11]C4. Without immunotherapy, mortality historically exceeded 15%; with modern treatment, the case‑fatality rate is 3-10% ^[25]D5. Death is usually due to respiratory failure, autonomic instability, or sepsis ^[9]D5[125]D5. Among survivors, approximately 20% remain unable to walk independently at 6 months, and a similar proportion die or have persistent disability despite immunotherapy ^{[25]D5[115]A1a}. Regional variation is pronounced: 1‑year independent walking rates range from 91% in Asia to 69% in Bangladesh, and mortality from 2% (Asia) to 17% (Bangladesh) ^[10]B2b.

Prognostic Models

Two validated clinical tools stratify outcome early. The modified Erasmus GBS Outcome Score (mEGOS) uses age, preceding diarrhoea, and Medical Research Council sumscore at admission or day 7 to predict inability to walk unaided at 6 months; the area under the curve (AUC) is 0.84-0.87 at day 7 ^[47]B2b. The Erasmus GBS Respiratory Insufficiency Score (EGRIS) predicts need for mechanical ventilation within the first week and has been validated internationally (AUC ≥ 0.80) ^[117]B2b.

Predictors of Poor Outcome

A second IVIG course does not improve outcome in patients with poor prognosis (mEGOS ≥ 6) and increases serious adverse events (35% vs 16%) ^[113]A1b.

Residual Symptoms and Long‑term Recovery

Motor recovery is often incomplete. In a prospective cohort, 5.9% could not walk independently at 6 months; residual symptoms included positive sensory symptoms (42.6%), fatigue (30.9%), subjective limb weakness (29.4%), and occupational change (48%) ^[120]B2b. Pain and fatigue may persist for months to years ^[25]D5. In pregnancy, maternal mortality is 5.2% and complete recovery occurs in only 35% ^[119]C4.

Pearl: Use the mEGOS at day 7 and the EGRIS at admission to identify high‑risk patients (poor outcome, respiratory failure) and to set realistic expectations with patients and families - these scores outperform clinical intuition ^{[47]B2b[117]B2b}.

Prognosis in GBS is heavily influenced by age and comorbidities, and these factors become central when managing special populations. Each group requires tailored diagnostic vigilance and treatment modifications to optimize outcomes.

Pediatrics

Children with GBS present distinct challenges. The axonal subtype (acute motor axonal neuropathy, AMAN) is particularly common in Mexican children, accounting for 38% of cases in one prospective series, and is associated with diarrhea and a seasonal peak from July to September ^[198]B2b. Children with AMAN may worsen during hospitalization, unlike those with demyelinating forms ^[198]B2b. The differential diagnosis of acute ataxia in children includes GBS/Miller Fisher syndrome variants in approximately 6.6% of cases (expected value), making hyporeflexia a critical distinguishing feature ^[202]A1a. Nerve ultrasound may show mild, proximal nerve enlargement in pediatric GBS, aiding diagnosis when electrodiagnostic studies are inconclusive ^[203]B2a.

Treatment modifications: IVIG 0.4 g/kg/day for 5 days is standard; therapeutic plasma exchange (PE) is also effective and was used successfully in a 4-year-old with malaria-associated GBS (5 exchanges over 10 days) ^[93]C4. The American Academy of Neurology recommends PE as established therapy for severe GBS in children (Level A) ^[8]A1c. Prognosis is generally favorable, but children with bulbar weakness or autonomic dysfunction require ICU monitoring ^[119]C4.

Pregnancy

GBS onset during pregnancy carries substantial maternal and obstetric risk. In a systematic review of 101 cases, symptom onset was most frequent in the third trimester (52.5%) ^[119]C4. Limb weakness (98%) and areflexia (87.6%) predominated; acute inflammatory demyelinating polyneuropathy accounted for 70% of subtypes ^[119]C4. ICU admission occurred in 64%, mechanical ventilation in 45%, and maternal mortality was 5.2% ^[119]C4. Bulbar weakness (OR 5.29) and autonomic dysfunction (OR 7.17) strongly predicted ICU need ^[119]C4. Obstetric outcomes included cesarean delivery in 54.8%, preterm birth in 36%, and low birthweight in one-third; neonatal survival was 85.6% ^[119]C4.

Treatment: Both IVIG and PE are safe in pregnancy. PE was associated with no maternal complications and term deliveries in a case series of early-gestation neurological disorders, including one GBS patient ^[108]C4. Zika virus infection during pregnancy is linked to both GBS and fetal microcephaly, underscoring the need for vector avoidance in endemic areas ^[30]D5. Delivery planning should involve multidisciplinary teams; vaginal delivery is possible if maternal respiratory status is stable, but cesarean rates are high due to maternal compromise ^[119]C4. Breastfeeding is not contraindicated with IVIG or PE.

Elderly

Age is an independent risk factor for death in GBS (p < 0.001) ^[57]B2b. Mortality at 6 months is 2.8% overall but rises sharply in elderly patients, particularly those requiring mechanical ventilation ^[57]B2b. Most deaths occur during the recovery phase from respiratory or cardiovascular complications, not the acute phase ^[57]B2b. Clinical action: Elderly patients should have a lower threshold for ICU admission and prolonged monitoring even after neurologic improvement begins. Treatment with IVIG or PE follows standard dosing, but careful attention to fluid balance and cardiac status is essential.

Immunocompromised

Data on GBS in immunocompromised hosts are limited. Management follows the same principles, but IVIG may be preferred over PE in patients with active infections or central line risks. Vaccination safety surveillance networks include GBS as an outcome of interest, and background rates (e.g., 21.5 cases per 10 million within 6 weeks of influenza vaccination in the UK) help contextualize post-vaccination events ^[201]D5.

Pearl: In pregnant women with GBS, bulbar weakness and autonomic dysfunction are the strongest predictors of ICU admission (OR 5.29 and 7.17, respectively), prompt recognition of these features should trigger early transfer to a unit capable of mechanical ventilation and multidisciplinary obstetric care ^[119]C4.

The preceding section highlighted the unique considerations for pregnant women and children with GBS. For all populations, prevention centers on reducing exposure to known infectious triggers and optimizing vaccine strategies.

Primary Prevention

Avoiding infections that trigger GBS is the cornerstone of primary prevention. Campylobacter jejuni is the most common antecedent pathogen, followed by cytomegalovirus, Epstein-Barr virus, SARS-CoV-2, and Zika virus ^{[209]B3b[88]B2b}. Food hygiene (thorough cooking of poultry, handwashing) reduces C. jejuni exposure. During arbovirus outbreaks, mosquito avoidance measures are critical ^[76]B2a. Vaccination against influenza and COVID-19 reduces the risk of infection and thereby the risk of post-infectious GBS. The net benefit of vaccination far outweighs the small vaccine-associated risk (see below).

Secondary Prevention

GBS is typically monophasic; recurrence occurs in fewer than 5% of adults. In children with biallelic RCC1 variants, however, recurrence is common and often fatal (15 of 24 children died) ^[80]C4. For typical GBS, no specific secondary prevention exists beyond avoiding known triggers. Patients with a history of GBS should be counseled that subsequent infections may rarely trigger a new episode, but the absolute risk is very low.

Screening and Surveillance

No population-based screening for GBS is recommended. Clinicians should maintain a high index of suspicion in patients presenting with progressive, symmetric weakness within 6 weeks of an infectious illness or vaccination. For patients with a history of GBS, no routine surveillance is indicated; they should be advised to seek evaluation promptly if new neurologic symptoms develop.

Vaccine-Related Considerations

SARS-CoV-2 infection itself increases GBS risk substantially (OR 6.30) ^[99]B3b. Thus, vaccination reduces overall GBS risk by preventing infection. For patients with prior GBS, SARS-CoV-2 vaccination appears safe: a prospective cohort of 162 patients found no recurrences after vaccination ^[166]B2b.

Patient Education

Patients should be educated to recognize early GBS symptoms, progressive limb weakness, paresthesias, facial weakness, or difficulty swallowing, and to seek immediate medical attention. The importance of routine vaccinations (influenza, COVID-19) should be emphasized, with reassurance that the benefits of preventing infection far exceed the rare risk of vaccine-associated GBS.

Pearl: The risk of GBS from SARS-CoV-2 infection (OR 6.30) is approximately 15-fold higher than the risk from any COVID-19 vaccine, making vaccination strongly advisable even in patients with a history of GBS.